Patents by Inventor Mohamed Ghonim

Mohamed Ghonim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PARP-1 and methods of use thereof
    Patent number: 12121518
    Abstract: The invention is directed to roles for low doses of PARP-1 inhibitors and synergistic combinations thereof to treat disease.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: October 22, 2024
    Assignee: THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSI AND AGRICULTURAL AND MECHANICAL COLLEGE
    Inventors: Hamid Boulares, Mohamed Ghonim
  • Genetically engineered T cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistence
    Patent number: 11857574
    Abstract: A population of genetically engineered T cells, comprising a disrupted Reg1 gene and/or a disrupted TGFBRII gene. Such genetically engineered T cells may comprise further genetic modifications, for example, a disrupted CD70 gene. The population of genetically engineered T cells exhibit one or more of (a) improved cell growth activity; (b) enhanced persistence; and (c) reduced T cell exhaustion, (d) enhanced cytotoxicity activity, (e) resistant to inhibitory effects induced by TGF-b, and (f) resistant to inhibitory effects by fibroblasts and/or inhibitory factors secreted thereby, as compared to non-engineered T cell counterparts.
    Type: Grant
    Filed: November 10, 2022
    Date of Patent: January 2, 2024
    Assignee: CRISPR Therapeutics AG
    Inventors: Mary-Lee Dequeant, Demetrios Kalaitzidis, Mohammed Ghonime
  • ANTI-CD19 CAR-T CELLS WITH MULTIPLE GENE EDITS AND THERAPEUTIC USES THEREOF
    Publication number: 20230303713
    Abstract: Genetically engineered T cells expressing a chimeric antigen receptor (CAR) targeting CD19 and having multiple genetic edits, including a disrupted TRAC gene, a disrupted ?2M gene, a disrupted Regnase 1 gene, and/or a disrupted TGFBRII gene. Also provided herein are methods of making such genetically engineered T cells and methods of using the genetically engineered T cells in cancer treatment.
    Type: Application
    Filed: March 22, 2023
    Publication date: September 28, 2023
    Inventors: Mohammed Ghonime, Jonathan Alexander TERRETT, Demetrios KALAITZIDIS, Mary-Lee Dequeant
  • GENETICALLY ENGINEERED T CELLS WITH REGNASE-1 AND/OR TGFBRII DISRUPTION HAVE IMPROVED FUNCTIONALITY AND PERSISTENCE
    Publication number: 20230263828
    Abstract: A population of genetically engineered T cells, comprising a disrupted Reg1 gene and/or a disrupted TGFBRII gene. Such genetically engineered T cells may comprise further genetic modifications, for example, a disrupted CD70 gene. The population of genetically engineered T cells exhibit one or more of (a) improved cell growth activity; (b) enhanced persistence; and (c) reduced T cell exhaustion, (d) enhanced cytotoxicity activity, (e) resistant to inhibitory effects induced by TGF-b, and (f) resistant to inhibitory effects by fibroblasts and/or inhibitory factors secreted thereby, as compared to non-engineered T cell counterparts.
    Type: Application
    Filed: November 10, 2022
    Publication date: August 24, 2023
    Inventors: Mary-Lee Dequeant, Demetrios Kalaitzidis, Mohammed Ghonime
  • PARP-1 and methods of use thereof
    Patent number: 11723906
    Abstract: The invention is directed to roles for PARP-1 in disease.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: August 15, 2023
    Assignee: The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Hamid Boulares, Mohamed Ghonim, Amir Al-Khami, Augusto Ochoa
  • Genetically engineered t cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistence
    Patent number: 11679130
    Abstract: A population of genetically engineered T cells, comprising a disrupted Reg1 gene and/or a disrupted TGFBRII gene. Such genetically engineered T cells may comprise further genetic modifications, for example, a disrupted CD70 gene. The population of genetically engineered T cells exhibit one or more of (a) improved cell growth activity; (b) enhanced persistence; and (c) reduced T cell exhaustion, (d) enhanced cytotoxicity activity, (e) resistant to inhibitory effects induced by TGF-b, and (f) resistant to inhibitory effects by fibroblasts and/or inhibitory factors secreted thereby, as compared to non-engineered T cell counterparts.
    Type: Grant
    Filed: October 4, 2021
    Date of Patent: June 20, 2023
    Assignee: CRISPR Therapeutics AG
    Inventors: Mary-Lee Dequeant, Demetrios Kalaitzidis, Mohammed Ghonime
  • Genetically engineered T cells with regnase-1 and/or TGFBRII disruption have improved functionality and persistence
    Patent number: 11679131
    Abstract: A population of genetically engineered T cells, comprising a disrupted Reg1 gene and/or a disrupted TGFBRII gene. Such genetically engineered T cells may comprise further genetic modifications, for example, a disrupted CD70 gene. The population of genetically engineered T cells exhibit one or more of (a) improved cell growth activity; (b) enhanced persistence; and (c) reduced T cell exhaustion, (d) enhanced cytotoxicity activity, (e) resistant to inhibitory effects induced by TGF-b, and (f) resistant to inhibitory effects by fibroblasts and/or inhibitory factors secreted thereby, as compared to non-engineered T cell counterparts.
    Type: Grant
    Filed: October 4, 2021
    Date of Patent: June 20, 2023
    Assignee: CRISPR Therapeutics AG
    Inventors: Mary-Lee Dequeant, Demetrios Kalaitzidis, Mohammed Ghonime
  • Genetically engineered t cells with regnase-1 and/or TGFBRII disruption have improved functionality and persistence
    Patent number: 11497773
    Abstract: A population of genetically engineered T cells, comprising a disrupted Reg1 gene and/or a disrupted TGFBRII gene. Such genetically engineered T cells may comprise further genetic modifications, for example, a disrupted CD70 gene. The population of genetically engineered T cells exhibit one or more of (a) improved cell growth activity; (b) enhanced persistence; and (c) reduced T cell exhaustion, (d) enhanced cytotoxicity activity, (e) resistant to inhibitory effects induced by TGF-b, and (f) resistant to inhibitory effects by fibroblasts and/or inhibitory factors secreted thereby, as compared to non-engineered T cell counterparts.
    Type: Grant
    Filed: October 4, 2021
    Date of Patent: November 15, 2022
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Mary-Lee Dequeant, Demetrios Kalaitzidis, Mohammed Ghonime
  • GENETICALLY ENGINEERED T CELLS WITH REGNASE-1 AND/OR TGFBRII DISRUPTION HAVE IMPROVED FUNCTIONALITY AND PERSISTENCE
    Publication number: 20220088077
    Abstract: A population of genetically engineered T cells, comprising a disrupted Reg1 gene and/or a disrupted TGFBRII gene. Such genetically engineered T cells may comprise further genetic modifications, for example, a disrupted CD70 gene. The population of genetically engineered T cells exhibit one or more of (a) improved cell growth activity; (b) enhanced persistence; and (c) reduced T cell exhaustion, (d) enhanced cytotoxicity activity, (e) resistant to inhibitory effects induced by TGF-b, and (f) resistant to inhibitory effects by fibroblasts and/or inhibitory factors secreted thereby, as compared to non-engineered T cell counterparts.
    Type: Application
    Filed: October 4, 2021
    Publication date: March 24, 2022
    Inventors: Mary-Lee Dequeant, Demetrios Kalaitzidis, Mohammed Ghonime
  • GENETICALLY ENGINEERED T CELLS WITH REGNASE-1 AND/OR TGFBRII DISRUPTION HAVE IMPROVED FUNCTIONALITY AND PERSISTENCE
    Publication number: 20220090012
    Abstract: A population of genetically engineered T cells, comprising a disrupted Reg1 gene and/or a disrupted TGFBRII gene. Such genetically engineered T cells may comprise further genetic modifications, for example, a disrupted CD70 gene. The population of genetically engineered T cells exhibit one or more of (a) improved cell growth activity; (b) enhanced persistence; and (c) reduced T cell exhaustion, (d) enhanced cytotoxicity activity, (e) resistant to inhibitory effects induced by TGF-b, and (f) resistant to inhibitory effects by fibroblasts and/or inhibitory factors secreted thereby, as compared to non-engineered T cell counterparts.
    Type: Application
    Filed: September 23, 2021
    Publication date: March 24, 2022
    Inventors: Mary-Lee Dequeant, Demetrios Kalaitzidis, Mohammed Ghonime
  • GENETICALLY ENGINEERED T CELLS WITH REGNASE-1 AND/OR TGFBRII DISRUPTION HAVE IMPROVED FUNCTIONALITY AND PERSISTENCE
    Publication number: 20220088078
    Abstract: A population of genetically engineered T cells, comprising a disrupted Reg1 gene and/or a disrupted TGFBRII gene. Such genetically engineered T cells may comprise further genetic modifications, for example, a disrupted CD70 gene. The population of genetically engineered T cells exhibit one or more of (a) improved cell growth activity; (b) enhanced persistence; and (c) reduced T cell exhaustion, (d) enhanced cytotoxicity activity, (e) resistant to inhibitory effects induced by TGF-b, and (f) resistant to inhibitory effects by fibroblasts and/or inhibitory factors secreted thereby, as compared to non-engineered T cell counterparts.
    Type: Application
    Filed: October 4, 2021
    Publication date: March 24, 2022
    Inventors: Mary-Lee Dequeant, Demetrios Kalaitzidis, Mohammed Ghonime
  • GENETICALLY ENGINEERED T CELLS WITH REGNASE-1 AND/OR TGFBRII DISRUPTION HAVE IMPROVED FUNCTIONALITY AND PERSISTENCE
    Publication number: 20220016173
    Abstract: A population of genetically engineered T cells, comprising a disrupted Reg1 gene and/or a disrupted TGFBRII gene. Such genetically engineered T cells may comprise further genetic modifications, for example, a disrupted CD70 gene. The population of genetically engineered T cells exhibit one or more of (a) improved cell growth activity; (b) enhanced persistence; and (c) reduced T cell exhaustion, (d) enhanced cytotoxicity activity, (e) resistant to inhibitory effects induced by TGF-b, and (f) resistant to inhibitory effects by fibroblasts and/or inhibitory factors secreted thereby, as compared to non-engineered T cell counterparts.
    Type: Application
    Filed: October 4, 2021
    Publication date: January 20, 2022
    Inventors: Mary-Lee Dequeant, Demetrios Kalaitzidis, Mohammed Ghonime
  • GENETICALLY ENGINEERED CAR T CELLS THAT SECRET INTERLEUKIN-12 AND THERAPEUTIC USES THEREOF
    Publication number: 20210363212
    Abstract: Genetically engineered immune cells such as T cells capable of secreting an interleukin-12 protein, for example, upon activation of the T cells. Such genetically engineered immune cells may further express a chimeric antigen receptor (CAR) targeting an antigen of interest, e.g., a tumor-associated antigen, a disrupted T cell receptor alpha chain constant (TRAC) gene, a disrupted beta-2-microglubulin (?2M) gene, a disrupted gene encoding the antigen of interest, or a combination thereof.
    Type: Application
    Filed: May 21, 2021
    Publication date: November 25, 2021
    Inventors: Mohammed Ghonime, Demetrios Kalaitzidis, Jason Sagert, Jonathan Alexander Terrett
  • PARP-1 AND METHODS OF USE THEREOF
    Publication number: 20200230134
    Abstract: The invention is directed to roles for low doses of PARP-1 inhibitors and synergistic combinations thereof to treat disease.
    Type: Application
    Filed: January 14, 2020
    Publication date: July 23, 2020
    Inventors: Hamid Boulares, Mohamed Ghonim
  • PARP-1 AND METHODS OF USE THEREOF
    Publication number: 20200069682
    Abstract: The invention is directed to roles for PARP-1 in disease.
    Type: Application
    Filed: September 9, 2019
    Publication date: March 5, 2020
    Inventors: Hamid Boulares, Mohamed Ghonim, Amir Al-Khami, Augusto Ochoa